I think the following can be moved from Phase I to Phase II.
Cambrex to Produce Serum for Trial
Cambrex to Make Serum for Merrimack Pharmaceuticals Autoimmune Disease Study.
Cambrex Corp. said Tuesday one of its subsidiaries will produce a serum for a Merrimack Pharmaceuticals clinical study on autoimmune disease treatments.
The subsidiary, Cambrex Bio Science Hopkinton Inc., will produce trial quantities of Merrimack's lead drug candidate, MM-093, for the Phase II study. Privately held, Cambridge, Mass.-based Merrimack is conducting the study to determine the serum's effectiveness on a range of autoimmune diseases including rheumatoid arthritis, multiple sclerosis and psoriasis.
Terms of the deal were not disclosed.
Cambrex and its subsidiaries focus on products and services for the drug-discovery industry.
Source: Yahoo Finance Copyright © 2006 The Associated Press.